Enveda targets asthma, eczema and weight maintenance with its first drug programs

Enveda says its first two drug programs target unmet medical needs. The company has not started efforts to treat cancer. One program aims to produce a safe oral, nonsteroidal medicine for asthma and atopic dermatitis, also known as eczema; Enveda says no nonsteroidal oral asthma medicine has been approved in more than 25 years.

The second program is based on a hormone produced after sprinting and is being developed as a once-daily pill. Enveda believes it could help people maintain their weight and metabolic health over the long term. The company says many people taking GLP-1 medication may be off it within one or two years, and describes the pill as a potential off-ramp for 55 million Americans over the next seven years.